Sections
| Title | Starting Page | Number of Pages |
|---|
| 1 Table of Contents | 2 | 20 |
| 1.1 List of Tables | 13 | 8 |
| 1.2 List of Figures | 21 | 1 |
| 2 Introduction | 22 | 1 |
| 2.1 Injectable Drug Delivery Overview | 22 | 1 |
| 3 Products under Development | 23 | 6 |
| 3.1 Injectable Drug Delivery - Pipeline Products by Stage of Development | 23 | 1 |
| 3.2 Injectable Drug Delivery - Pipeline Products by Segment | 24 | 1 |
| 3.3 Injectable Drug Delivery - Pipeline Products by Territory | 25 | 1 |
| 3.4 Injectable Drug Delivery - Pipeline Products by Regulatory Path | 26 | 1 |
| 3.5 Injectable Drug Delivery - Pipeline Products by Estimated Approval Date | 27 | 1 |
| 3.6 Injectable Drug Delivery - Ongoing Clinical Trials | 28 | 1 |
| 4 Injectable Drug Delivery - Pipeline Products under Development by Companies | 29 | 8 |
| 4.1 Injectable Drug Delivery Companies - Pipeline Products by Stage of Development | 29 | 4 |
| 4.2 Injectable Drug Delivery - Pipeline Products by Stage of Development | 33 | 4 |
| 5 Injectable Drug Delivery Companies and Product Overview | 37 | 146 |
| 5.1 Aciont Inc. Company Overview | 37 | 1 |
| 5.1.1 Aciont Inc. Pipeline Products &Ongoing Clinical Trials Overview | 37 | 2 |
| 5.2 Actavis Inc. Company Overview | 39 | 1 |
| 5.2.1 Actavis Inc. Pipeline Products &Ongoing Clinical Trials Overview | 39 | 1 |
| 5.3 AdrenaCard, Inc. Company Overview | 40 | 1 |
| 5.3.1 AdrenaCard, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 40 | 1 |
| 5.4 Allergan, Inc. Company Overview | 41 | 1 |
| 5.4.1 Allergan, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 41 | 1 |
| 5.5 Alsensa ApS Company Overview | 42 | 1 |
| 5.5.1 Alsensa ApS Pipeline Products &Ongoing Clinical Trials Overview | 42 | 1 |
| 5.6 AMAG Pharmaceuticals, Inc. Company Overview | 43 | 1 |
| 5.6.1 AMAG Pharmaceuticals, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 43 | 2 |
| 5.7 Amgen Inc. Company Overview | 45 | 1 |
| 5.7.1 Amgen Inc. Pipeline Products &Ongoing Clinical Trials Overview | 45 | 2 |
| 5.8 Antares Pharma, Inc. Company Overview | 47 | 1 |
| 5.8.1 Antares Pharma, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 47 | 6 |
| 5.9 Anterion Therapeutics, Inc. (Inactive) Company Overview | 53 | 1 |
| 5.9.1 Anterion Therapeutics, Inc. (Inactive) Pipeline Products &Ongoing Clinical Trials Overview | 53 | 3 |
| 5.10 Arnali, LLC Company Overview | 56 | 1 |
| 5.10.1 Arnali, LLC Pipeline Products &Ongoing Clinical Trials Overview | 56 | 1 |
| 5.11 Artemes Technologies, Inc. Company Overview | 57 | 1 |
| 5.11.1 Artemes Technologies, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 57 | 1 |
| 5.12 AstraZeneca Plc Company Overview | 58 | 1 |
| 5.12.1 AstraZeneca Plc Pipeline Products &Ongoing Clinical Trials Overview | 58 | 2 |
| 5.13 Atanse, Inc. Company Overview | 60 | 1 |
| 5.13.1 Atanse, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 60 | 2 |
| 5.14 AzureBio, S.L. Company Overview | 62 | 1 |
| 5.14.1 AzureBio, S.L. Pipeline Products &Ongoing Clinical Trials Overview | 62 | 1 |
| 5.15 Becton, Dickinson and Company Company Overview | 63 | 1 |
| 5.15.1 Becton, Dickinson and Company Pipeline Products &Ongoing Clinical Trials Overview | 63 | 4 |
| 5.16 Bespak Europe Ltd. Company Overview | 67 | 1 |
| 5.16.1 Bespak Europe Ltd. Pipeline Products &Ongoing Clinical Trials Overview | 67 | 3 |
| 5.17 Biodel Inc. Company Overview | 70 | 1 |
| 5.17.1 Biodel Inc. Pipeline Products &Ongoing Clinical Trials Overview | 70 | 2 |
| 5.18 BioMarin Pharmaceutical Inc. Company Overview | 72 | 1 |
| 5.18.1 BioMarin Pharmaceutical Inc. Pipeline Products &Ongoing Clinical Trials Overview | 72 | 2 |
| 5.19 BioRestorative Therapies, Inc. Company Overview | 74 | 1 |
| 5.19.1 BioRestorative Therapies, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 74 | 2 |
| 5.20 Boston University Company Overview | 76 | 1 |
| 5.20.1 Boston University Pipeline Products &Ongoing Clinical Trials Overview | 76 | 1 |
| 5.21 BTG Plc Company Overview | 77 | 1 |
| 5.21.1 BTG Plc Pipeline Products &Ongoing Clinical Trials Overview | 77 | 2 |
| 5.22 Burke Pharmaceuticals, LLC Company Overview | 79 | 1 |
| 5.22.1 Burke Pharmaceuticals, LLC Pipeline Products &Ongoing Clinical Trials Overview | 79 | 1 |
| 5.23 Callisyn Biomedical Inc Company Overview | 80 | 1 |
| 5.23.1 Callisyn Biomedical Inc Pipeline Products &Ongoing Clinical Trials Overview | 80 | 3 |
| 5.24 Cambridge Consultants Limited Company Overview | 83 | 1 |
| 5.24.1 Cambridge Consultants Limited Pipeline Products &Ongoing Clinical Trials Overview | 83 | 1 |
| 5.25 Case Western Reserve University Company Overview | 84 | 1 |
| 5.25.1 Case Western Reserve University Pipeline Products &Ongoing Clinical Trials Overview | 84 | 1 |
| 5.26 Cincinnati Children's Hospital Medical Center Company Overview | 85 | 1 |
| 5.26.1 Cincinnati Children's Hospital Medical Center Pipeline Products &Ongoing Clinical Trials Overview | 85 | 1 |
| 5.27 Clearside BioMedical, Inc. Company Overview | 86 | 1 |
| 5.27.1 Clearside BioMedical, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 86 | 4 |
| 5.28 Consort Medical plc Company Overview | 90 | 1 |
| 5.28.1 Consort Medical plc Pipeline Products &Ongoing Clinical Trials Overview | 90 | 1 |
| 5.29 Credence MedSystems, Inc. Company Overview | 91 | 1 |
| 5.29.1 Credence MedSystems, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 91 | 1 |
| 5.30 CrossCoat Medical LLC Company Overview | 92 | 1 |
| 5.30.1 CrossCoat Medical LLC Pipeline Products &Ongoing Clinical Trials Overview | 92 | 1 |
| 5.31 Cytosial Biomedic, S.a.s. Company Overview | 93 | 1 |
| 5.31.1 Cytosial Biomedic, S.a.s. Pipeline Products &Ongoing Clinical Trials Overview | 93 | 1 |
| 5.32 DALI Medical Devices Ltd. Company Overview | 94 | 1 |
| 5.32.1 DALI Medical Devices Ltd. Pipeline Products &Ongoing Clinical Trials Overview | 94 | 4 |
| 5.33 Delcath Systems, Inc. Company Overview | 98 | 1 |
| 5.33.1 Delcath Systems, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 98 | 5 |
| 5.34 DelSite, Inc. (Inactive) Company Overview | 103 | 1 |
| 5.34.1 DelSite, Inc. (Inactive) Pipeline Products &Ongoing Clinical Trials Overview | 103 | 1 |
| 5.35 Elcam Medical Company Overview | 104 | 1 |
| 5.35.1 Elcam Medical Pipeline Products &Ongoing Clinical Trials Overview | 104 | 4 |
| 5.36 EmboMedics Company Overview | 108 | 1 |
| 5.36.1 EmboMedics Pipeline Products &Ongoing Clinical Trials Overview | 108 | 1 |
| 5.37 Emergent BioSolutions Inc. Company Overview | 109 | 1 |
| 5.37.1 Emergent BioSolutions Inc. Pipeline Products &Ongoing Clinical Trials Overview | 109 | 2 |
| 5.38 Eveon SAS Company Overview | 111 | 1 |
| 5.38.1 Eveon SAS Pipeline Products &Ongoing Clinical Trials Overview | 111 | 1 |
| 5.39 Ghent University Company Overview | 112 | 1 |
| 5.39.1 Ghent University Pipeline Products &Ongoing Clinical Trials Overview | 112 | 1 |
| 5.40 Hannover Medical School Company Overview | 113 | 1 |
| 5.40.1 Hannover Medical School Pipeline Products &Ongoing Clinical Trials Overview | 113 | 1 |
| 5.41 Indian Institute of Science Company Overview | 114 | 1 |
| 5.41.1 Indian Institute of Science Pipeline Products &Ongoing Clinical Trials Overview | 114 | 1 |
| 5.42 Inovio Pharmaceuticals, Inc. Company Overview | 115 | 1 |
| 5.42.1 Inovio Pharmaceuticals, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 115 | 2 |
| 5.43 LyoGo Company Overview | 117 | 1 |
| 5.43.1 LyoGo Pipeline Products &Ongoing Clinical Trials Overview | 117 | 1 |
| 5.44 Medicom Innovation Partner a/s Company Overview | 118 | 1 |
| 5.44.1 Medicom Innovation Partner a/s Pipeline Products &Ongoing Clinical Trials Overview | 118 | 1 |
| 5.45 Meridian Medical Technologies, Inc. Company Overview | 119 | 1 |
| 5.45.1 Meridian Medical Technologies, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 119 | 1 |
| 5.46 Mertiva AB Company Overview | 120 | 1 |
| 5.46.1 Mertiva AB Pipeline Products &Ongoing Clinical Trials Overview | 120 | 1 |
| 5.47 Microchips Biotech, Inc. Company Overview | 121 | 1 |
| 5.47.1 Microchips Biotech, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 121 | 2 |
| 5.48 Midatech Pharma Plc Company Overview | 123 | 1 |
| 5.48.1 Midatech Pharma Plc Pipeline Products &Ongoing Clinical Trials Overview | 123 | 2 |
| 5.49 Milestone Scientific Inc. Company Overview | 125 | 1 |
| 5.49.1 Milestone Scientific Inc. Pipeline Products &Ongoing Clinical Trials Overview | 125 | 3 |
| 5.50 North Carolina State University Company Overview | 128 | 1 |
| 5.50.1 North Carolina State University Pipeline Products &Ongoing Clinical Trials Overview | 128 | 2 |
| 5.51 Ocelus Company Overview | 130 | 1 |
| 5.51.1 Ocelus Pipeline Products &Ongoing Clinical Trials Overview | 130 | 1 |
| 5.52 Oval Medical Technologies Limited Company Overview | 131 | 1 |
| 5.52.1 Oval Medical Technologies Limited Pipeline Products &Ongoing Clinical Trials Overview | 131 | 1 |
| 5.53 Particle Therapeutics Ltd Company Overview | 132 | 1 |
| 5.53.1 Particle Therapeutics Ltd Pipeline Products &Ongoing Clinical Trials Overview | 132 | 1 |
| 5.54 Pfizer Inc. Company Overview | 133 | 1 |
| 5.54.1 Pfizer Inc. Pipeline Products &Ongoing Clinical Trials Overview | 133 | 2 |
| 5.55 Portal Instruments, Inc. Company Overview | 135 | 1 |
| 5.55.1 Portal Instruments, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 135 | 1 |
| 5.56 pSivida Corp. Company Overview | 136 | 1 |
| 5.56.1 pSivida Corp. Pipeline Products &Ongoing Clinical Trials Overview | 136 | 5 |
| 5.57 Ratio, Inc. Company Overview | 141 | 1 |
| 5.57.1 Ratio, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 141 | 2 |
| 5.58 Recon Therapeutics, LLC Company Overview | 143 | 1 |
| 5.58.1 Recon Therapeutics, LLC Pipeline Products &Ongoing Clinical Trials Overview | 143 | 1 |
| 5.59 Replenish Inc Company Overview | 144 | 1 |
| 5.59.1 Replenish Inc Pipeline Products &Ongoing Clinical Trials Overview | 144 | 2 |
| 5.60 RepliCel Life Sciences, Inc. Company Overview | 146 | 1 |
| 5.60.1 RepliCel Life Sciences, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 146 | 1 |
| 5.61 RetinaPharma Technologies, Inc. Company Overview | 147 | 1 |
| 5.61.1 RetinaPharma Technologies, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 147 | 1 |
| 5.62 Rx Safes, Inc. Company Overview | 148 | 1 |
| 5.62.1 Rx Safes, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 148 | 1 |
| 5.63 Scandinavian Health Ltd Company Overview | 149 | 1 |
| 5.63.1 Scandinavian Health Ltd Pipeline Products &Ongoing Clinical Trials Overview | 149 | 1 |
| 5.64 Shire Plc Company Overview | 150 | 1 |
| 5.64.1 Shire Plc Pipeline Products &Ongoing Clinical Trials Overview | 150 | 2 |
| 5.65 Spine Smith, LP Company Overview | 152 | 1 |
| 5.65.1 Spine Smith, LP Pipeline Products &Ongoing Clinical Trials Overview | 152 | 1 |
| 5.66 Sun Pharmaceutical Industries Limited Company Overview | 153 | 1 |
| 5.66.1 Sun Pharmaceutical Industries Limited Pipeline Products &Ongoing Clinical Trials Overview | 153 | 2 |
| 5.67 TCB medical devices Company Overview | 155 | 1 |
| 5.67.1 TCB medical devices Pipeline Products &Ongoing Clinical Trials Overview | 155 | 1 |
| 5.68 Teva Pharmaceutical Industries Ltd. Company Overview | 156 | 1 |
| 5.68.1 Teva Pharmaceutical Industries Ltd. Pipeline Products &Ongoing Clinical Trials Overview | 156 | 2 |
| 5.69 Texas Tech University Company Overview | 158 | 1 |
| 5.69.1 Texas Tech University Pipeline Products &Ongoing Clinical Trials Overview | 158 | 1 |
| 5.70 TheraKine Ltd. (Inactive) Company Overview | 159 | 1 |
| 5.70.1 TheraKine Ltd. (Inactive) Pipeline Products &Ongoing Clinical Trials Overview | 159 | 2 |
| 5.71 Unilife Corporation Company Overview | 161 | 1 |
| 5.71.1 Unilife Corporation Pipeline Products &Ongoing Clinical Trials Overview | 161 | 3 |
| 5.72 United Therapeutics Corporation Company Overview | 164 | 1 |
| 5.72.1 United Therapeutics Corporation Pipeline Products &Ongoing Clinical Trials Overview | 164 | 2 |
| 5.73 University College London Company Overview | 166 | 1 |
| 5.73.1 University College London Pipeline Products &Ongoing Clinical Trials Overview | 166 | 1 |
| 5.74 University of Auckland Company Overview | 167 | 1 |
| 5.74.1 University of Auckland Pipeline Products &Ongoing Clinical Trials Overview | 167 | 1 |
| 5.75 University of Calgary Company Overview | 168 | 1 |
| 5.75.1 University of Calgary Pipeline Products &Ongoing Clinical Trials Overview | 168 | 1 |
| 5.76 University of California, Irvine Company Overview | 169 | 1 |
| 5.76.1 University of California, Irvine Pipeline Products &Ongoing Clinical Trials Overview | 169 | 1 |
| 5.77 University of California, San Diego Company Overview | 170 | 1 |
| 5.77.1 University of California, San Diego Pipeline Products &Ongoing Clinical Trials Overview | 170 | 1 |
| 5.78 University of California, San Francisco Company Overview | 171 | 1 |
| 5.78.1 University of California, San Francisco Pipeline Products &Ongoing Clinical Trials Overview | 171 | 1 |
| 5.79 University of Delaware Company Overview | 172 | 1 |
| 5.79.1 University of Delaware Pipeline Products &Ongoing Clinical Trials Overview | 172 | 1 |
| 5.80 University of Dundee Company Overview | 173 | 1 |
| 5.80.1 University of Dundee Pipeline Products &Ongoing Clinical Trials Overview | 173 | 1 |
| 5.81 University of Florida Company Overview | 174 | 1 |
| 5.81.1 University of Florida Pipeline Products &Ongoing Clinical Trials Overview | 174 | 3 |
| 5.82 University of Missouri Company Overview | 177 | 1 |
| 5.82.1 University of Missouri Pipeline Products &Ongoing Clinical Trials Overview | 177 | 1 |
| 5.83 University of Saskatchewan Company Overview | 178 | 1 |
| 5.83.1 University of Saskatchewan Pipeline Products &Ongoing Clinical Trials Overview | 178 | 1 |
| 5.84 University of Texas at Austin Company Overview | 179 | 1 |
| 5.84.1 University of Texas at Austin Pipeline Products &Ongoing Clinical Trials Overview | 179 | 2 |
| 5.85 Urodelia SA Company Overview | 181 | 1 |
| 5.85.1 Urodelia SA Pipeline Products &Ongoing Clinical Trials Overview | 181 | 1 |
| 5.86 Vanderbilt University Company Overview | 182 | 1 |
| 5.86.1 Vanderbilt University Pipeline Products &Ongoing Clinical Trials Overview | 182 | 1 |
| 6 Injectable Drug Delivery- Recent Developments | 183 | 216 |
| 6.1 Aug 29, 2016: Mylan to Launch First Generic to EpiPen Auto-Injector at a List Price of $300 per Two-Pack Carton, a More than 50% Discount to the Brand Product | 183 | 1 |
| 6.2 Aug 29, 2016: pSivida Announces 13 New Patents Issued or Allowed | 184 | 1 |
| 6.3 Aug 29, 2016: Catalent Reports Fourth Quarter and Fiscal Year 2016 Results | 184 | 3 |
| 6.4 Aug 25, 2016: Mylan Taking Immediate Action To Further Enhance Access To EpiPen (Epinephrine Injection, USP) Auto-Injector | 187 | 1 |
| 6.5 Aug 25, 2016: Medtronic Reports First Quarter Financial Results | 188 | 2 |
| 6.6 Aug 24, 2016: Senators Ask FDA to Account for Any Alternatives to the EpiPen Amid Product Cost Increases | 190 | 1 |
| 6.7 Aug 24, 2016: Hillary Clinton Statement on EpiPen Pricing | 191 | 1 |
| 6.8 Aug 24, 2016: Milestone Scientific Begins Transition From a Product Development to a Business Development Company | 191 | 1 |
| 6.9 Aug 22, 2016: Mylan's Commitment to EpiPen (epinephrine injection, USP) Auto-Injector Access | 192 | 1 |
| 6.10 Aug 17, 2016: Consort Medical Announces Directorate Change | 193 | 1 |
| 6.11 Aug 16, 2016: Delcath Announces Second Quarter Financial Results | 194 | 1 |
| 6.12 Aug 15, 2016: MRI Interventions Announces 2016 Second Quarter and Six Month Results | 195 | 4 |
| 6.13 Aug 12, 2016: Milestone Scientific Reports 34% Increase in Revenue for the Second Quarter of 2016 | 199 | 1 |
| 6.14 Aug 11, 2016: Biodel Reports Third Quarter Fiscal Year 2016 Financial Results | 200 | 1 |
| 6.15 Aug 11, 2016: Clearside Biomedical Reports Second Quarter 2016 Financial Results | 200 | 1 |
| 6.16 Aug 09, 2016: Primary Endpoint Met in pSivida's Utilization Study of New Medidur Inserter with Smaller Diameter Needle | 201 | 1 |
| 6.17 Aug 09, 2016: BioMarin Pharma Prices Public Offering of Shares for USD720 Million | 202 | 1 |
| 6.18 Aug 09, 2016: Mylan Reports Strong Second Quarter 2016 Results Including Total Revenues Up 8% | 202 | 3 |
| 6.19 Aug 09, 2016: Antares Pharma Reports Second Quarter 2016 Operating and Financial Results | 205 | 2 |
| 6.20 Aug 09, 2016: Halozyme Reports Second Quarter 2016 Financial Results | 207 | 1 |
| 6.21 Aug 05, 2016: Caverion delivers a Large Project for Novo Nordisk s new insulin production facility in Hillerod, Denmark | 208 | 1 |
| 6.22 Aug 05, 2016: Novo Nordisk increased adjusted operating profit by 8% in local currencies in the first six months of 2016 | 209 | 1 |
| 6.23 Aug 04, 2016: Teva Reports Second Quarter 2016 Results | 209 | 5 |
| 6.24 Aug 04, 2016: BD Announces Results For 2016 Third Fiscal Quarter | 214 | 1 |
| 6.25 Aug 04, 2016: Merck Lifts Forecast Following Good Second Quarter | 215 | 3 |
| 6.26 Aug 04, 2016: Emergent BioSolutions Reports Second Quarter and Six Months 2016 Financial Results | 218 | 3 |
| 6.27 Aug 03, 2016: pSivida Names Dario Paggiarino, M.D. as Chief Medical Officer | 221 | 1 |
| 6.28 Aug 02, 2016: Merck and Allergan May Acquire Biogen | 221 | 1 |
| 6.29 Aug 02, 2016: Pfizer Reports Second-Quarter 2016 Results | 221 | 4 |
| 6.30 Aug 02, 2016: Shire Delivers Strong Q2 2016 Revenue Growth; Upgrades Outlook | 225 | 5 |
| 6.31 Aug 01, 2016: BCWorld Pharm Raises USD1.8 Million in Private Placement of Shares | 230 | 1 |
| 6.32 Aug 01, 2016: Aptevo Therapeutics Completes Separation from Emergent BioSolutions | 230 | 1 |
| 6.33 Aug 01, 2016: Clearside Biomedical Announces Promotion of Glenn Noronha, Ph.D. to Chief Scientific Officer and Jennifer M. Kissner, Ph.D. to Vice President, Clinical Development | 230 | 1 |
| 6.34 Aug 01, 2016: Emergent BioSolutions Completes Spin-Off of Aptevo Therapeutics | 231 | 1 |
| 6.35 Jul 29, 2016: Adamis Pharma to Raise USD11 Million in Private Placement of Units | 231 | 1 |
| 6.36 Jul 29, 2016: Sanofi Announces Q2 2016 Results | 232 | 7 |
| 6.37 Jul 29, 2016: Royalty report for Q2 2016 and update on lixisenatide (Lyxumia/Adlyxin) and iGlarLixi | 239 | 1 |
| 6.38 Jul 28, 2016: BioCorRx Enters into Licensing Agreement with Therakine | 240 | 1 |
| 6.39 Jul 28, 2016: Unilife Announces New Leadership Team and Targeted Growth Strategy | 240 | 2 |
| 6.40 Jul 28, 2016: Alkermes Reports Second Quarter 2016 Financial Results | 242 | 2 |
| 6.41 Jul 28, 2016: West Announces Second Quarter 2016 Results | 244 | 2 |
| 6.42 Jul 28, 2016: United Therapeutics Reports Second Quarter 2016 Financial Results | 246 | 1 |
| 6.43 Jul 28, 2016: BD Names R. Andrew Eckert To Board Of Directors | 247 | 1 |
| 6.44 Jul 28, 2016: AstraZeneca: H1 2016 Results | 247 | 12 |
| 6.45 Jul 27, 2016: Marathon Pharmaceuticals Names Two New Executive Team Members | 259 | 1 |
| 6.46 Jul 26, 2016: Dr. Reddy s Q1 FY17 Financial Results | 260 | 1 |
| 6.47 Jul 21, 2016: Teva Pharma Raises USD304 Million in Public Offering of 0.125% Notes Due 2018 | 261 | 1 |
| 6.48 Jul 21, 2016: Teva Pharma Raises USD354.6 Million in Public Offering of 1% Notes Due 2025 | 262 | 1 |
| 6.49 Jul 21, 2016: Teva Pharma Raises USD354.6 Million in Public Offering of 0.5% Notes Due 2022 | 262 | 1 |
| 6.50 Jul 21, 2016: Biogen Reports Second Quarter 2016 Revenues of $2.9 Billion | 263 | 2 |
| 6.51 Jul 20, 2016: Milestone Scientific Files 510(k) Application for Marketing Clearance of the Epidural Instrument and Disposables in the United States | 265 | 1 |
| 6.52 Jul 20, 2016: Data Shows pSivida's Tethadur Provides Prolonged, Sustained Release of Avastin With High Drug Efficacy | 266 | 1 |
| 6.53 Jul 19, 2016: MilliporeSigma Starts Construction on $115 Million Multi-faceted Life Science Campus in Burlington, Massachusetts | 267 | 1 |
| 6.54 Jul 18, 2016: Delcath Announces Acceptance Of Abstracts For Poster Presentation At CIRSE 2016 | 267 | 1 |
| 6.55 Jul 18, 2016: Teva Pharma Raises USD3.5 Billion in Public Offering of 3.15% Notes Due 2026 | 268 | 1 |
| 6.56 Jul 18, 2016: Teva Pharma Raises USD1.5 Billion in Public Offering of 1.4% Notes Due 2018 | 268 | 1 |
| 6.57 Jul 18, 2016: Teva Pharma Raises USD3 Billion in Public Offering of 2.2% Notes Due 2021 | 269 | 1 |
| 6.58 Jul 18, 2016: Teva Pharma Raises USD3 Billion in Public Offering of 2.8% Notes Due 2023 | 269 | 1 |
| 6.59 Jul 18, 2016: Teva Pharma Raises USD2 Billion in Public Offering of 4.1% Notes Due 2046 | 270 | 1 |
| 6.60 Jul 18, 2016: Teva Pharma Raises USD2 Billion in Public Offering of 1.7% Notes Due 2019 | 270 | 1 |
| 6.61 Jul 18, 2016: Unilife Submits Plan to Regain Compliance with NASDAQ Requirements | 271 | 1 |